Eisai files kidney cancer drug in Europe

Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.
The file is centred on Phase II showing that the drug significantly extended progression-free survival (PFS) when added to treatment with Novartis’ Afinitor (everolimus); those given the combination regimen experienced a median PFS of 14.6 months versus 5.5 months for those taking everolimus alone.
 
Read the full story HERE on PhamaTimes